FDA report: Paxlovid is effective in high-risk adults

FDA staff say Pfizer's clinical trial results on COVID-19 oral antiviral Paxlovid (nirmatrelvir and ritonavir) support the drug's use in adults at high risk of progressing to severe disease, hospitalization, or death. In the EPIC-HR trial treatment with Paxlovid demonstrated a 5.6% absolute reduction, or 86% relative reduction vs. placebo in unvaccinated, high-risk adults. FDA's Antimicrobial Drugs Advisory Committee will meet March 16 to discuss whether to grant full approval to Paxlovid for the treatment of mild to moderate COVID-19 in high-risk adults.